HD-OPM Archive
Topics › Lp(a)

Lp(a)HORIZON NEJM: pelacarsen cut Lp(a) 78% with no trend toward fewer events

Louis Nervegna · Nov 07, 2026 · ♥ 6 reactions · 4 comments · original Facebook post
Lp(a)PCSK9, ezetimibe & newer drugs
AI summary & key facts

Louis summarizes the Lp(a)HORIZON paper in NEJM. Pelacarsen lowered Lp(a) by 78% but there was no reduction in MACE, not even a trend, with slightly more events on the drug (non-significant). Subgroups with Lp(a) above 90 mg/dL showed no extra benefit over 70-90, and serious adverse events were actually higher on placebo.

The full results of the Lp(a) HORIZON trial were presented at the AHA Scientific Sessions this morning.

A journal paper was simultaneously released online in the New England Journal of Medicine:

Paper · N Engl J Med · 2026Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).Conclusion: Pelacarsen did not result in a lower risk of major adverse cardiovascular events than placebo at a median follow-up of 4.7 years. (Funded by Novartis; Lp[a]HORIZON ClinicalTrials.gov number, NCT04023552.)See also in NEJM Evidence: Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).nejm.org

The PowerPoint slides from the presentation can be found in this post: ↪ Slides from the Lp(a)HORIZON AHA 2026 presentation by Steven Nissen.

As previoisly announced, there was no benefit after ~5 years on the drug Pelacarsen. The drug dramatically lowered Lp(a) by 78%, but there was no reduction in hard outcomes (MACE).

There was not even a trend towards benefit.

Sometimes you do see a trend towards benefit which does not reach statistical significance. This can hint that there might still be a mild treatment effect, which is harder to detect. That was not the case here. In fact, there were slightly more MACE events in the Pelacarsen group than in the placebo group (non-significant).

Subgroup analysis also did not show any extra benefit in people with very high Lp(a) > 90mg/dL compared to people with more modestly high levels of 70mg/dL < Lp(a) < 90mg/dL. This is another strong hint that there is not even a mild treatment effect from this particular drug.

The drug did appear to be reasonably well tolerated. Serious adverse events were higher in the placebo group than on Pelacarsen.

Quoted:

A total of 8350 patients underwent randomization, with 8322 included in the efficacy analysis; 4157 patients were assigned to receive pelacarsen, and 4165 to receive placebo. The mean age of the patients was 59.7 years, and 27.0% were women. The median lipoprotein(a) level at baseline was 236 nmol per liter. At 12 months, the lipoprotein(a) level was 64.4 nmol per liter in the pelacarsen group and 233.4 nmol per liter in the placebo group. The median follow-up was 4.7 years. A primary end-point event occurred in 511 patients (12.3%) in the pelacarsen group and in 503 (12.1%) in the placebo group (hazard ratio, 1.02, 95% confidence interval [CI], 0.90 to 1.15, P=0.76). Among patients with a baseline lipoprotein(a) level of at least 90 mg per deciliter, a primary end-point event occurred in 402 of 3266 patients (12.3%) in the pelacarsen group and in 403 of 3274 (12.3%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.87 to 1.15; P=0.99). Serious adverse events occurred in 1553 of 4166 patients (37.3%) who received pelacarsen and in 1709 of 4154 (41.1%) who received placebo.

#lpaHD #horizonHD #pelacarsenHD

Paper · N Engl J Med · 2026Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)Pelacarsen, an antisense oligonucleotide, reduces serum levels of lipoprotein(a). However, the effect of pelacarsen on cardiovascular outcomes remains uncertain. We conducted an international, rand...nejm.org

Research cited

← newer: Joel Kahn teases that the Lp(a)HORIZON trial was a bustolder: Sauna works the heart like light cardio and lowered blood pr →